Mayur Jain is a seasoned scientist with extensive experience in oncology and gene therapy research. Currently a scientist at Minervax ApS since October 2024, Mayur previously worked at Hansa Biopharma from April 2021 to May 2024, where responsibilities included serving as a project manager for in-house gene therapy projects and implementing the electronic lab notebook system, along with developing neutralizing antibody assays and writing analytical reports. Prior roles included a biomedical analyst at Region Skåne, a postdoctoral researcher at Lund University focusing on myeloproliferative neoplasms, and a Ph.D. candidate at Linkoping University conducting research on Akt kinase in breast cancer. Mayur holds a Ph.D. in Oncology and Cancer Biology and a Master's in Medical Bioscience from Linköping University, as well as a Bachelor of Pharmacy from Savitribai Phule Pune University.